Completed PHASE3 INTERVENTIONAL 3-arm NCT00255151

Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis

Sponsor: Takeda

Conditions Esophagitis, Peptic Esophagitis, Reflux

Interventions Dexlansoprazole MR Placebo

Updated 7 times since 2017 Last updated: Feb 1, 2012 Started: Jan 31, 2006 Primary completion: Nov 30, 2006 Completion: Nov 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Esophagitis, Peptic and Esophagitis, Reflux, this trial is completed. The trial is conducted by Takeda and has accumulated 7 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Albuquerque, United States , Amarillo, United States , Anderson, United States , Anniston, United States , Atlanta, United States , Azusa, United States , Baton Rouge, United States , Bellevue, United States , Bismarck, United States and 88 more locations